Pharmacology

Psilocybin is a prodrug. When ingested, alkaline phosphatases in the gut wall and liver rapidly cleave the phosphate group, converting psilocybin to psilocin — the active compound that crosses the blood-brain barrier and binds serotonin receptors. This conversion occurs within 20–30 minutes of ingestion, with plasma psilocin concentrations peaking at approximately 80 minutes and the subjective experience following with a slight lag. The terminal half-life of psilocin is 2–3 hours, which explains the typical 4–6 hour duration of a full psychedelic session.

The primary mechanism is agonism at the 5-HT2A receptor — specifically at pyramidal neurons in cortical layer V, where psilocin binding triggers increased glutamate release, AMPA receptor activation, and downstream BDNF expression. This cascade produces the enhanced neural connectivity and plasticity that underlies both the acute psychedelic experience and the lasting therapeutic effects. The 5-HT2A receptor's distribution, heavily concentrated in associative cortices that integrate sensory and conceptual information, explains why psilocybin specifically alters self-referential cognition rather than producing simple stimulation or sedation.

Psilocybin also binds with lower affinity to 5-HT1A receptors (producing anxiolytic effects), dopamine D3 receptors (potentially contributing to its anti-addictive properties), and sigma-1 receptors (involved in neuroplasticity and neuroprotection). This multi-target pharmacology distinguishes psilocybin from selective serotonergic compounds and may explain its broad therapeutic efficacy across conditions as different as depression, addiction, OCD, and end-of-life anxiety.

Tolerance develops rapidly and completely — a second dose taken within 3–5 days produces virtually no effect due to 5-HT2A receptor downregulation. This built-in desensitization mechanism means psilocybin has essentially zero abuse potential by pharmacological definition. It also informs clinical protocol design: sessions are spaced weeks apart not by convention, but by neurochemical necessity and to allow the therapeutic integration process to unfold.